AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
To own ScanSource, you need to be comfortable with a mid-sized distributor that is trying to pivot more of its business toward higher-margin, recurring technology and communications solutions while still operating on thin net margins. The latest full-year results and the 6% to 10% sales growth outlook for 2027 broadly support that story, and the recent share price gain suggests the market has welcomed the update rather than seeing it as a major reset of expectations. In the short term, key catalysts remain execution on the Launch Point initiatives, integration of recent acquisitions and continued share repurchases, with the new earnings guidance reinforcing, rather than redefining, those themes. The bigger risks look unchanged: low returns on equity, modest forecast growth and execution risk as leadership responsibilities shift on a slightly smaller board.
However, one governance and capital allocation issue in particular is worth a closer look for shareholders. ScanSource's shares have been on the rise but are still potentially undervalued by 15%. Find out what it's worth.Explore 2 other fair value estimates on ScanSource - why the stock might be worth as much as 8% more than the current price!
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
Every day counts. These free picks are already gaining attention. See them before the crowd does:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com